EntityWire

EntityWire / EIN 85-3863315

Employer with a benefit plan

SIO GENE THERAPIES

EIN 85-3863315. What DOL Form 5500-SF filings (EFAST2) and SEC EDGAR company filings say about this entity, with the source and date on every fact. Latest record 2025-04-29.

Employer with a benefit plan ยท SEC filer

SIO GENE THERAPIES

Also filed as Axovant Gene Therapies Ltd.; Axovant Sciences Ltd.; Roivant Neurosciences Ltd.

130 WEST 42ND STREET, NEW YORK, NY 10036

EIN

85-3863315

Benefit plan 1, 2024 filing

SIO GENE THERAPIES 401(K) PLAN

DOL · 2025-04-29

Participants (start of year)

1

DOL · 2025-04-29

Plan assets (end of year)

$0

DOL · 2025-04-29

Plan features

code 2F2G2J2K2T3D

DOL · 2025-04-29

Plan type

Multiemployer plan

DOL · 2025-04-29

Business code (NAICS)

325410

DOL · 2025-04-29

Benefit plan 1, 2024 filing

SIO GENE THERAPIES 401(K) PLAN

DOL · 2025-04-29

Participants (start of year)

74

DOL · 2025-04-29

Plan assets (end of year)

$29,262

DOL · 2025-04-29

Plan features

code 2F2G2J2K2T3D

DOL · 2025-04-29

Plan type

Multiemployer plan

DOL · 2025-04-29

Business code (NAICS)

325410

DOL · 2025-04-29

Benefit plan 1, 2023 filing

SIO GENE THERAPIES 401(K) PLAN

DOL · 2024-06-20

Participants (start of year)

81

DOL · 2024-06-20

From DOL Form 5500-SF filings (EFAST2) · SEC EDGAR company filings. Latest record 2025-04-29.

What this record is

Public federal filings that carry this EIN, shown as filed. Nothing here is scraped from the IRS and nothing is inferred.

What it is not

Registry status, formation date, and registered agent come from the New York Department of State, Division of Corporations; search the New York registry.

If something is wrong

A name, address, or classification here is what the source published. To correct the source, file with it; to have this page removed, see corrections and removal.

Look up another business

Free. Federal filings and state registries, stamped with their source and date.